Researchers from Caltech, the University of Washington, the University of Pennsylvania, the University at Albany, the Rockefeller University, the University of Edinburgh, Creative BioSolutions, LLC (Miami, FL), HDT Bio (Seattle, WA), Acuitas Therapeutics (Vancouver, Canada), and Ingenza Ltd. (RoslIn, United Kingdom) have developed and tested a new COVID-19 vaccine candidate called mosaic-8 that has shown potential to protect against different types of sarbecoviruses, including SARS-CoV-2 (the virus that causes COVID-19) and its variants. The mosaic-8 vaccine is made up of nanoparticles that elicit antibodies against conserved features of sarbecoviruses. Each nanoparticle contains pieces of eight different sarbecoviruses. These pieces are regions of the viruses' spike protein, called receptor-binding domains (RBDs), that are crucial for the virus to infect a cell. Mosaic-8 is now being prepared for initial human clinical trials.
An official website of the United States government.
